Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes, but evidence in adults aged ≥75 years remains limited, particularly compared with dipeptidyl peptidase-4 inhibitors (DPP-4i).

We conducted a target trial emulation using linked administrative claims and health examination data in Japan. Individuals aged ≥75 years with type 2 diabetes who newly initiated an SGLT2i or DPP-4i were identified. Intention-to-treat (ITT) effects were estimated using inverse probability weighting, with a 1-month induction period for mortality, cardiovascular and renal outcomes.

The study included 8486 individuals (2204 SGLT2i users, 6282 DPP-4i users). After a 1-month induction period, SGLT2i initiation was associated with lower all-cause mortality (hazard ratio [HR] 0.677, 95% confidence interval [CI] 0.500-0.916) and lower risk of end-stage renal disease or dialysis (HR 0.374, 95% CI 0.157-0.890). No clear differences were observed for heart failure hospitalisation (HR 1.103, 95% CI 0.854-1.426) or myocardial infarction (HR 1.015, 95% CI 0.768-1.341) in the ITT analysis. Stroke occurred more frequently among SGLT2i users (HR 1.420, 95% CI 1.165-1.828), although this finding should be interpreted cautiously.

Among adults aged ≥75 years with type 2 diabetes, SGLT2i initiation was associated with lower all-cause mortality and renal risk compared with DPP-4i initiation. The higher observed stroke risk requires cautious interpretation because residual confounding, competing mortality and heterogeneity in vulnerable older adults may contribute to this signal.